Cargando…

Common transcriptional signatures of neuropathic pain

The dorsal root ganglia (DRG) are key structures in nociception and chronic pain disorders. Several gene expression studies of DRG in preclinical pain models have been performed, but it is unclear if consistent gene changes are identifiable. We, therefore, compared several recent RNA-Seq data sets o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pokhilko, Alexandra, Nash, Anthony, Cader, M. Zameel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302324/
https://www.ncbi.nlm.nih.gov/pubmed/32107361
http://dx.doi.org/10.1097/j.pain.0000000000001847
_version_ 1783547821770670080
author Pokhilko, Alexandra
Nash, Anthony
Cader, M. Zameel
author_facet Pokhilko, Alexandra
Nash, Anthony
Cader, M. Zameel
author_sort Pokhilko, Alexandra
collection PubMed
description The dorsal root ganglia (DRG) are key structures in nociception and chronic pain disorders. Several gene expression studies of DRG in preclinical pain models have been performed, but it is unclear if consistent gene changes are identifiable. We, therefore, compared several recent RNA-Seq data sets on the whole DRG in rodent models of nerve injury. Contrary to previous findings, we show hundreds of common differentially expressed genes and high positive correlation between studies, despite model and species differences. We also find, in contrast to previous studies, that 60% of the common rodent gene response after injury is likely to occur in nociceptors of the DRG. Substantial expression changes are observed at a 1-week time-point, with smaller changes in the same genes at a later 3- to 4-week time-point. However, a subset of genes shows a similar magnitude of changes at both early and late time-points, suggesting their potential involvement in the maintenance of chronic pain. These genes are centred around suppression of endogenous opioid signalling. Reversal of this suppression could allow endogenous and exogenous opioids to exert their analgesic functions and may be an important strategy for treating chronic pain disorders. Currently used drugs, such as amitriptyline and duloxetine, do not seem to appropriately modulate many of the critical pain genes and indeed may transcriptionally suppress endogenous opioid signalling further.
format Online
Article
Text
id pubmed-7302324
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-73023242020-06-29 Common transcriptional signatures of neuropathic pain Pokhilko, Alexandra Nash, Anthony Cader, M. Zameel Pain Research Paper The dorsal root ganglia (DRG) are key structures in nociception and chronic pain disorders. Several gene expression studies of DRG in preclinical pain models have been performed, but it is unclear if consistent gene changes are identifiable. We, therefore, compared several recent RNA-Seq data sets on the whole DRG in rodent models of nerve injury. Contrary to previous findings, we show hundreds of common differentially expressed genes and high positive correlation between studies, despite model and species differences. We also find, in contrast to previous studies, that 60% of the common rodent gene response after injury is likely to occur in nociceptors of the DRG. Substantial expression changes are observed at a 1-week time-point, with smaller changes in the same genes at a later 3- to 4-week time-point. However, a subset of genes shows a similar magnitude of changes at both early and late time-points, suggesting their potential involvement in the maintenance of chronic pain. These genes are centred around suppression of endogenous opioid signalling. Reversal of this suppression could allow endogenous and exogenous opioids to exert their analgesic functions and may be an important strategy for treating chronic pain disorders. Currently used drugs, such as amitriptyline and duloxetine, do not seem to appropriately modulate many of the critical pain genes and indeed may transcriptionally suppress endogenous opioid signalling further. Wolters Kluwer 2020-07 2020-02-26 /pmc/articles/PMC7302324/ /pubmed/32107361 http://dx.doi.org/10.1097/j.pain.0000000000001847 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Research Paper
Pokhilko, Alexandra
Nash, Anthony
Cader, M. Zameel
Common transcriptional signatures of neuropathic pain
title Common transcriptional signatures of neuropathic pain
title_full Common transcriptional signatures of neuropathic pain
title_fullStr Common transcriptional signatures of neuropathic pain
title_full_unstemmed Common transcriptional signatures of neuropathic pain
title_short Common transcriptional signatures of neuropathic pain
title_sort common transcriptional signatures of neuropathic pain
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302324/
https://www.ncbi.nlm.nih.gov/pubmed/32107361
http://dx.doi.org/10.1097/j.pain.0000000000001847
work_keys_str_mv AT pokhilkoalexandra commontranscriptionalsignaturesofneuropathicpain
AT nashanthony commontranscriptionalsignaturesofneuropathicpain
AT cadermzameel commontranscriptionalsignaturesofneuropathicpain